BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

...are best-in-class therapeutics for other genomically-defined lung cancers with a high response rate, a high CNS response...
BioCentury | Jun 9, 2017
Clinical News

Puma reports additional Phase II data for neratinib in breast cancer with brain metastases

...trial showing that once-daily 240 mg oral neratinib (HKI-272, PB272) plus capecitabine led to a CNS response...
...no escalating steroid use and no progressive neurologic symptoms; progression-free survival (PFS), overall survival (OS), CNS response...
BioCentury | Jun 2, 2017
Clinical News

Puma reports Phase II data for neratinib in HER2-positive breast cancer with brain metastases

...escalating steroid use and no progressive neurologic symptoms. Secondary endpoints include progression-free survival (PFS), OS, CNS response...
...no escalating steroid use and no progressive neurologic symptoms; progression-free survival (PFS), overall survival (OS), CNS response...
BioCentury | May 25, 2015
Clinical News

Alecensa alectinib: Phase II data

...rate (ORR) (Part 2); disease control rate (DCR), duration of objective response, progression-free survival (PFS), CNS response...
BioCentury | Jun 9, 2014
Clinical News

Oral neratinib: Phase II data

...brain metastases Endpoint: Composite CNS objective response rate (ORR); progression-free survival (PFS), overall survival (OS), CNS response...
BioCentury | Sep 7, 2009
Company News

CNS Response board of directors update

CNS Response Inc. (OTCBB:CNSO), Costa Mesa, Calif. Business: Diagnostic, Supply/Service Appointed: John Pappajohn, president and owner of Equity Dynamics Inc. and Pappajohn Capital Resources; and Tommy Thompson, partner at Akin Gump Strauss Hauer & Feld...
BioCentury | Sep 7, 2009
Financial News

CNS Response completes private placement of units

CNS Response Inc. (OTCBB:CNSO), Costa Mesa, Calif. Business: Diagnostic, Supply/Service Date completed: 8/27/09 Type: Private placement of units Raised: $2.1 million Units: 38 Price: $54,000 (unit) Shares after offering: 41.8 million Investors: Accredited investors Note:...
Items per page:
1 - 7 of 7
BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

...are best-in-class therapeutics for other genomically-defined lung cancers with a high response rate, a high CNS response...
BioCentury | Jun 9, 2017
Clinical News

Puma reports additional Phase II data for neratinib in breast cancer with brain metastases

...trial showing that once-daily 240 mg oral neratinib (HKI-272, PB272) plus capecitabine led to a CNS response...
...no escalating steroid use and no progressive neurologic symptoms; progression-free survival (PFS), overall survival (OS), CNS response...
BioCentury | Jun 2, 2017
Clinical News

Puma reports Phase II data for neratinib in HER2-positive breast cancer with brain metastases

...escalating steroid use and no progressive neurologic symptoms. Secondary endpoints include progression-free survival (PFS), OS, CNS response...
...no escalating steroid use and no progressive neurologic symptoms; progression-free survival (PFS), overall survival (OS), CNS response...
BioCentury | May 25, 2015
Clinical News

Alecensa alectinib: Phase II data

...rate (ORR) (Part 2); disease control rate (DCR), duration of objective response, progression-free survival (PFS), CNS response...
BioCentury | Jun 9, 2014
Clinical News

Oral neratinib: Phase II data

...brain metastases Endpoint: Composite CNS objective response rate (ORR); progression-free survival (PFS), overall survival (OS), CNS response...
BioCentury | Sep 7, 2009
Company News

CNS Response board of directors update

CNS Response Inc. (OTCBB:CNSO), Costa Mesa, Calif. Business: Diagnostic, Supply/Service Appointed: John Pappajohn, president and owner of Equity Dynamics Inc. and Pappajohn Capital Resources; and Tommy Thompson, partner at Akin Gump Strauss Hauer & Feld...
BioCentury | Sep 7, 2009
Financial News

CNS Response completes private placement of units

CNS Response Inc. (OTCBB:CNSO), Costa Mesa, Calif. Business: Diagnostic, Supply/Service Date completed: 8/27/09 Type: Private placement of units Raised: $2.1 million Units: 38 Price: $54,000 (unit) Shares after offering: 41.8 million Investors: Accredited investors Note:...
Items per page:
1 - 7 of 7